Delayed
Nasdaq Stockholm
06:52:11 2024-05-08 EDT
|
5-day change
|
1st Jan Change
|
0.53
SEK
|
+0.38%
|
|
-3.28%
|
+16.10%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
326.8
|
274.5
|
275.5
|
254.8
|
165.1
|
191
|
-
|
-
|
Enterprise Value (EV)
1 |
326.8
|
274.5
|
223.1
|
254.8
|
128.9
|
191
|
191
|
191
|
P/E ratio
|
-9.38
x
|
-8.59
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
41
x
|
-
|
-
|
-
|
-
|
5.37
x
|
6.82
x
|
EV / Revenue
|
-
|
41
x
|
-
|
-
|
-
|
-
|
5.37
x
|
6.82
x
|
EV / EBITDA
|
-
|
-8.85
x
|
-5.68
x
|
-4.52
x
|
-3.69
x
|
-4.44
x
|
-12.4
x
|
-91
x
|
EV / FCF
|
-
|
-8,524,750
x
|
-5,963,554
x
|
-4,650,020
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
145,236
|
145,236
|
217,972
|
264,887
|
361,739
|
361,739
|
-
|
-
|
Reference price
2 |
2.250
|
1.890
|
1.264
|
0.9620
|
0.4565
|
0.5280
|
0.5280
|
0.5280
|
Announcement Date
|
20-02-06
|
21-02-11
|
22-03-25
|
23-02-09
|
24-02-08
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
6.7
|
-
|
-
|
-
|
-
|
35.6
|
28
|
EBITDA
1 |
-
|
-31
|
-48.5
|
-56.4
|
-44.8
|
-43
|
-15.4
|
-2.1
|
EBIT
1 |
-
|
-32.3
|
-49.8
|
-57.9
|
-46.5
|
-43
|
-15.4
|
-2.1
|
Operating Margin
|
-
|
-482.09%
|
-
|
-
|
-
|
-
|
-43.26%
|
-7.5%
|
Earnings before Tax (EBT)
1 |
-
|
-32.2
|
-49.8
|
-
|
-45.8
|
-43
|
-15.4
|
-2.1
|
Net income
1 |
-34.1
|
-32.2
|
-49.8
|
-58.4
|
-45.8
|
-43
|
-15.4
|
-2.1
|
Net margin
|
-
|
-480.6%
|
-
|
-
|
-
|
-
|
-43.26%
|
-7.5%
|
EPS
|
-0.2400
|
-0.2200
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-32.2
|
-46.2
|
-54.8
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-480.6%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-06
|
21-02-11
|
22-03-25
|
23-02-09
|
24-02-08
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
52.4
|
-
|
36.2
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-32.2
|
-46.2
|
-54.8
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-145%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-06
|
21-02-11
|
22-03-25
|
23-02-09
|
24-02-08
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +16.10% | 17.66M | | +0.82% | 106B | | +8.12% | 23.47B | | -13.89% | 21.9B | | -6.17% | 18.77B | | -37.26% | 17.85B | | -10.98% | 16.78B | | +8.67% | 14.41B | | +41.08% | 12.86B | | +327.78% | 8.78B |
Bio Therapeutic Drugs
|